Overview

In order to utilize and communicate with patients effectively on the role of biosimilars within the healthcare system, clinicians need to have a fundamental understanding of their unique approval process and how these agents differ in relation to their reference drug and generic small molecule drugs. This Video Webcast is designed to provide healthcare professionals with an opportunity to make well-informed decisions about the safety and efficacy profiles of biosimilars, apply their appropriate clinical use, and learn how best to communicate treatment decisions to patients so that positive patient outcomes may be realized. 

Learning Objectives

  • Define biosimilar therapies, including how they differ from both their reference drug and small molecule generic agents.
  • Evaluate the most recent clinical evidence on biosimilar agents related to efficacy, safety, clinical implications for patient management, and value-based healthcare.
  • Assess strategies for enhancing the effective clinical use of biosimilars, including considerations for evaluating biosimilarity, interchangeability, and the extrapolation of clinical data across indications.
  • Identify primary-care driven opportunities for improving patient education and awareness of biosimilar therapies, including enhanced communication and shared decision-making, in order to optimize health outcomes.  


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement

pmiCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

pmiCME is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.


Designation Statement

This program has been approved for 1.25 contact hours of continuing education, which includes 0.58 hour of pharmacology.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 4 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.

Faculty Disclosures

The following financial relationships have been disclosed by faculty.

Jonathan Kay, MD

Advisory Board for Boehringer Ingelheim Pharmaceuticals, Inc.; Celltrion Healthcare Co.,Ltd.; Merck & Co., Inc.; Pfizer Inc.; Samsung Bioepis; Sandoz International GmbH; and UCB. Contracted Research for Pfizer Inc. and UCB. 

Andrew M. Evens, DO, MSc

Advisory Board for AbbVie Inc.; Acerta Pharma; Affimed; Bayer; Janssen Scientific Affairs, LLC; Pharmacyclics LLC; and Seattle Genetics, Inc. Contracted Research for Tesaro, Inc. 

Disclosures

The following financial relationships have been disclosed by faculty.

Commercial Supporter

Pfizer Inc.

Education Partner

CE Health Interactive


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.